Active, not recruitingPhase 2NCT03595124
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
Studying MiT family translocation renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- James I GellerChildren's Oncology Group
- Intervention
- Axitinib(drug)
- Enrollment
- 15 enrolled
- Eligibility
- All sexes
- Timeline
- 2019 – 2026
Study locations (30)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
- Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
- CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Kaiser Permanente-Anaheim, Anaheim, California, United States
- Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California, United States
- PCR Oncology, Arroyo Grande, California, United States
- Kaiser Permanente-Bellflower, Bellflower, California, United States
- Mercy Cancer Center - Carmichael, Carmichael, California, United States
- Mercy San Juan Medical Center, Carmichael, California, United States
- Kaiser Permanente Downey Medical Center, Downey, California, United States
- Mercy Cancer Center - Elk Grove, Elk Grove, California, United States
- Kaiser Permanente-Fontana, Fontana, California, United States
- Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03595124 on ClinicalTrials.gov